DashBio
Boston · Founded 2024 · $17.5M raised
- Headquarters
- Boston
- Founded
- 2024
- Business Model
- B2B
- Website
- dash.bio
- Total Funding
- $17.5M
- Last Round
- $11.0M Series ANov 2024
- Rounds
- 2
About
Dash Bio is a tech-first bioanalysis CRO built from day one around AI, robotics, and modern software rather than the traditional manual, error-prone bioanalysis model. Operating from its Boston headquarters, the company delivers sample analysis results in days instead of weeks, publishes pricing directly on its site for full transparency, and has raised $17.5M in funding to accelerate drug development timelines for biotech sponsors.
Summary
DashBio is a Biotech company based in Boston, founded in 2024. It has raised $17.5M in total across 2 rounds, most recently a $11.0M Series A round in Nov 2024. Investors include Freestyle Capital, The Aligned Fund and Swift Ventures.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Nov 2024
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
Alphabet-backed biotechnology company researching biology of aging and developing interventions t...
BridgeBio makes targeted treatments for genetic diseases.
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...